Dana-Farber Cancer Institute recently shared on LinkedIn:

“For more than a decade, a collaborative team of experts at Dana-Farber, with support from generous families, patient advocates, and the National Cancer Institute (NCI), carried out the scientific detective work that helped transform an orphaned drug into a medicine, tovorafenib, that has now been approved for young patients with relapsed or progressive pediatric low-grade glioma.

‘This is an example of what Dana-Farber is capable of. It’s a really nice example of just how much preclinical work goes into a discovery like this one. An approval for a pediatric tumor doesn’t happen very often. I think this Dana-Farber team can be very proud.’ – Karen D. Wright, MD.”

Source: Dana-Farber Cancer Institute/LinkedIn